UNICYCIVE THERAPEUTICS INC (UNCY) Stock Price & Overview
NASDAQ:UNCY • US90466Y2028
The current stock price of UNCY is 7.07 USD. Today UNCY is up by 4.28%. In the past month the price increased by 2.17%. In the past year, price increased by 25.33%.
UNCY Key Statistics
- Market Cap
- 151.934M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.95
- Dividend Yield
- N/A
UNCY Stock Performance
UNCY Stock Chart
UNCY Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to UNCY. When comparing the yearly performance of all stocks, UNCY is one of the better performing stocks in the market, outperforming 78.37% of all stocks.
UNCY Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to UNCY. While UNCY seems to be doing ok healthwise, there are quite some concerns on its profitability.
UNCY Earnings
UNCY Forecast & Estimates
14 analysts have analysed UNCY and the average price target is 47.43 USD. This implies a price increase of 570.86% is expected in the next year compared to the current price of 7.07.
UNCY Groups
Sector & Classification
UNCY Financial Highlights
Over the last trailing twelve months UNCY reported a non-GAAP Earnings per Share(EPS) of -3.95. The EPS increased by 61.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -105.21% | ||
| ROE | -192.09% | ||
| Debt/Equity | 0 |
UNCY Ownership
UNCY Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.26 | 413.319B | ||
| AMGN | AMGEN INC | 16.83 | 203.007B | ||
| GILD | GILEAD SCIENCES INC | 16.62 | 183.41B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.44 | 120.332B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.95 | 81.051B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.86 | 42.097B | ||
| INSM | INSMED INC | N/A | 31.351B | ||
| NTRA | NATERA INC | N/A | 29.344B | ||
| BIIB | BIOGEN INC | 12.48 | 27.007B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.41 | 21.856B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.914B | ||
| EXAS | EXACT SCIENCES CORP | 309.36 | 19.724B | ||
| MRNA | MODERNA INC | N/A | 19.468B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About UNCY
Company Profile
Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. The company is headquartered in Los Altos, California and currently employs 22 full-time employees. The company went IPO on 2021-06-17. The firm's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Company Info
UNICYCIVE THERAPEUTICS INC
4300 El Camino Real, Suite 210
Los Altos CALIFORNIA US
CEO: Shalabh Gupta
Employees: 22
Phone: 16503840642
UNICYCIVE THERAPEUTICS INC / UNCY FAQ
What does UNCY do?
Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. The company is headquartered in Los Altos, California and currently employs 22 full-time employees. The company went IPO on 2021-06-17. The firm's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
What is the current price of UNCY stock?
The current stock price of UNCY is 7.07 USD. The price increased by 4.28% in the last trading session.
Does UNICYCIVE THERAPEUTICS INC pay dividends?
UNCY does not pay a dividend.
What is the ChartMill rating of UNICYCIVE THERAPEUTICS INC stock?
UNCY has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is UNICYCIVE THERAPEUTICS INC worth?
UNICYCIVE THERAPEUTICS INC (UNCY) has a market capitalization of 151.93M USD. This makes UNCY a Micro Cap stock.
Can you provide the ownership details for UNCY stock?
You can find the ownership structure of UNICYCIVE THERAPEUTICS INC (UNCY) on the Ownership tab.
What is the Short Interest ratio of UNICYCIVE THERAPEUTICS INC (UNCY) stock?
The outstanding short interest for UNICYCIVE THERAPEUTICS INC (UNCY) is 8.78% of its float.